About Zinc finger protein 716
Zinc finger protein 716 (ZNF716) is a protein
from Homo sapiens identified by UniProt accession
A6NP11, 495 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Zinc finger protein 716 |
| UniProt accession | A6NP11 |
| Gene | ZNF716 |
| Organism | Homo sapiens |
| Length | 495 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- nasopharyngeal neoplasm · score 0.27
- retinitis pigmentosa · score 0.07
- injury · score 0.06
- Leber congenital amaurosis · score 0.05
- aniridia · score 0.05
- Aniridia-intellectual disability syndrome · score 0.04
- Familial ocular anterior segment mesenchymal dysgenesis · score 0.04
- congenital glaucoma · score 0.04
- retinitis pigmentosa 71 · score 0.04
- isolated optic nerve hypoplasia · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NP11-F1 | alphafold | PREDICTED | 70.77 | — |
Amino-acid sequence (495 residues)
MAKRPGPPGS REMGLLTFRD IAIEFSLAEW QCLDHAQQNL YRDVMLENYR NLVSLGIAVS KPDLITCLEQ NKEPQNIKRN EMVAKHPVTC SHFTQDLQSE QGIKDSLQKV ILRRYGKCGQ EDLQVKKCCK SVGECEVHKG GYNYVNQCLS ATQNKTFQTH KCVKVFGKFS NSNRHKTRHT GKKHFKCKND GKSFCMLSRL NQHQIIHTRE KSYKCEECGK SFNCSSTLTR HKRIHTGEKP YRCEECGKAF SWSASLTKHK RIHTGEKPYT CEERGKVFSR STLTNYKRIH TGEKPYTCEE CGKAFSRSST LTNHKRIHTG ERPYKCEECG KAFSLSSTLK KHKIVHTGEK LYTCEECGKA FTFSSTLNTH KRIHTGEKPY TCEECGKAFS LPSTFTYHKR THTGEKPYKC EECGKAFNCS STLKKHKIIH TGEKLYKCKE CGKAFTFSST LNTHKRIHTG EKPYKCEECD QTFKWHSSLA NHKNMHTGEK PYKYE
Explore Zinc finger protein 716 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets